Samstag, 31. Juli 2021
Navigation öffnen
Anzeige:
Imfinzi NSCLC
Imfinzi NSCLC
JOURNAL ONKOLOGIE – STUDIE

A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

Rekrutierend

NCT-Nummer:
NCT04576455

Studienbeginn:
November 2020

Letztes Update:
19.07.2021

Wirkstoff:
Fulvestrant or an Aromatase Inhibitor (Physician's Choice), LHRH Agonist, Giredestrant

Indikation (Clinical Trials):
Breast Neoplasms

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
Hoffmann-La Roche

Collaborator:
-

Studienleiter

Clinical Trials
Study Director
Hoffmann-La Roche

Kontakt

Reference Study ID Number: WO42312 www.roche.com/about_roche/roche_worldwide.htm
Kontakt:
Phone: 888-662-6728 (U.S. Only)
E-Mail: global-roche-genentech-trials@gene.com
» Kontaktdaten anzeigen

Studienlocations
(3 von 103)

Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg
63739 Aschaffenburg
(Bayern)
GermanyAktiv, nicht rekrutierend» Google-Maps
Frauenarzt-Zentrum Zehlendorf an der Teltower Eiche
14169 Berlin
(Berlin)
GermanyRekrutierend» Google-Maps
Kooperatives Mammazentrum Hamburg Krankenhaus Jerusalem
20357 Hamburg
(Hamburg)
GermanyRekrutierend» Google-Maps
St. Elisabeth-Krankenhaus; Brustzentrum
50935 Köln
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
St. Vincenz-Krankenhaus Paderborn; Haus 3 Frauenklinik
33098 Paderborn
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Oncologianova GmbH - Gesellschaft für Innovationen in der Onkologie
45659 Recklinghausen
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
G.Sund Gynäkologie Kompetenzzentrum; Praxis Dr. med. Carsten Hielscher
18439 Stralsund
(Mecklenburg-Vorpommern)
GermanyRekrutierend» Google-Maps
Northwest Georgia Oncology Centers PC - Marietta
30060 Marietta
United StatesRekrutierend» Google-Maps
Illinois Cancer Specialists
60005 Arlington Heights
United StatesRekrutierend» Google-Maps
St. Vincent Frontier Cancer Center
59101 Billings
United StatesRekrutierend» Google-Maps
University Hospitals Seidman Cancer Center
44106 Cleveland
United StatesRekrutierend» Google-Maps
Northwest Cancer Specialists - Portland (SW Barnes Rd)
97223 Tigard
United StatesRekrutierend» Google-Maps
Texas Oncology Cancer Center
78731 Austin
United StatesRekrutierend» Google-Maps
Texas Oncology - El Paso
79902 El Paso
United StatesRekrutierend» Google-Maps
Texas Oncology - Houston (Gessner)
77024 Houston
United StatesRekrutierend» Google-Maps
Texas Oncology, P.A. - Tyler; Tyler Cancer Center
75702 Tyler
United StatesRekrutierend» Google-Maps
Fundación CENIT para la Investigación en Neurociencias
C1125ABD Buenos Aires
ArgentinaRekrutierend» Google-Maps
Instituto Angel Roffo
1417 Ciudad Autonoma de Buenos Aires
ArgentinaRekrutierend» Google-Maps
Instituto de Investigaciones Metabolicas (Idim)
C1012AAR Ciudad Autonoma de Buenos Aires
ArgentinaRekrutierend» Google-Maps
Fundación Scherbovsky; General Department
5500 Mendoza
ArgentinaRekrutierend» Google-Maps
Hosp Provincial D. Centenarios; Oncology Dept
S2002KDS Rosario
ArgentinaAktiv, nicht rekrutierend» Google-Maps
Kinghorn Cancer Centre; St Vincents Hospital
2010 Darlinghurst
AustraliaRekrutierend» Google-Maps
Mater Hospital; Patricia Ritchie Centre for Cancer Care and Research
2059 North Sydney
AustraliaRekrutierend» Google-Maps
Sunshine Hospital
3021 St Albans
AustraliaAktiv, nicht rekrutierend» Google-Maps
Fiona Stanley Hospital - Medical Oncology
6150 Murdoch
AustraliaRekrutierend» Google-Maps
Pronutrir - suporte nutricional e quimioterapia ltda.
60810-180 Fortaleza
BrazilRekrutierend» Google-Maps
Hospital de Caridade de Ijui; Oncologia
98700-000 Ijui
BrazilRekrutierend» Google-Maps
Santa Casa de Misericordia de Porto Alegre
90050-170 Porto Alegre
BrazilRekrutierend» Google-Maps
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda
01317-001 Sao Paulo
BrazilRekrutierend» Google-Maps
Inst. Brasileiro de Controle Ao Cancer; Oncologia Clinica / Quimioterapia
04014-002 Sao Paulo
BrazilRekrutierend» Google-Maps
The First Hospital of Jilin University
130021 Changchun City
ChinaRekrutierend» Google-Maps
Sun Yet-sen University Cancer Center
510060 Guangzhou
ChinaRekrutierend» Google-Maps
Harbin Medical University Cancer Hospital
150081 Harbin
ChinaRekrutierend» Google-Maps
Fudan University Shanghai Cancer Center
200120 Shanghai City
ChinaRekrutierend» Google-Maps
First Affiliated Hospital of Medical College of Xi'an Jiaotong University
710061 Xi'an
ChinaRekrutierend» Google-Maps
Assuta Medical Center- Ashdod; Oncology
7747629 Ashdod
IsraelRekrutierend» Google-Maps
Hadassah Ein Karem Hospital; Oncology Dept
9112000 Jerusalem
IsraelAktiv, nicht rekrutierend» Google-Maps
Meir Medical Center; Oncology
4428164 Kfar-Saba
IsraelRekrutierend» Google-Maps
Rabin Medical Center; Oncology Dept
4941492 Petach Tikva
IsraelRekrutierend» Google-Maps
Kyungpook National University Medical Center
41404 Daegu
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Soon Chun Hyang University Cheonan Hospital
31151 Dongnam-gu, Cheonan-si
Korea, Republic ofRekrutierend» Google-Maps
National Cancer Center
10408 Goyang-si
Korea, Republic ofRekrutierend» Google-Maps
Seoul National University Hospital
03080 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Severance Hospital, Yonsei University Health System
03722 Seoul
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Asan Medical Center
05505 Seoul
Korea, Republic ofAktiv, nicht rekrutierend» Google-Maps
Gangnam Severance Hospital
06273 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Samsung Medical Center
06531 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Seoul St Mary's Hospital
06591 Seoul
Korea, Republic ofRekrutierend» Google-Maps
Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej
15-027 Bialystok
PolandRekrutierend» Google-Maps
Copernicus Podmiot Medyczny Sp. z o.o. Wojewodzkie Centrum Onkologii
80-219 Gdansk
PolandRekrutierend» Google-Maps
Narodowy Instytut Onkologii Odział w Gliwicach; Centrum Diagnostyki i Leczenia Chorób Piersi
44-102 Gliwice
PolandRekrutierend» Google-Maps
Szpital Uniwersytecki w Krakowie, Oddział Kliniczny Kliniki Onkologii
30-688 Kraków
PolandRekrutierend» Google-Maps
Centralny Szpital Kliniczny Mswia; Klinika onkologii, hematologii i chorob wewnetrznych
02-507 Warszawa
PolandRekrutierend» Google-Maps
Narodowy Inst.Onkologii im.Sklodowskiej-Curie Panstw.Inst.Bad; Klinika Nowtw.Piersi i Chir.Rekonstr
02-781 Warszawa
PolandAktiv, nicht rekrutierend» Google-Maps
Blokhin Cancer Research Center; Combined Treatment
115478 Moskva
Russian FederationAktiv, nicht rekrutierend» Google-Maps
Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic
420029 Kazan
Russian FederationRekrutierend» Google-Maps
Clinical Oncology Centre # 1; Chemotherapy Dept
350040 Krasnodar
Russian FederationRekrutierend» Google-Maps
Krasnoyarsk Regional Oncology Dispensary n.a. Krizhanovsky; Chemotherapy
660133 Krasnoyarsk
Russian FederationRekrutierend» Google-Maps
Murmansk Regional Clinical Hospital named after P.A. Bayandin
183047 Murmansk
Russian FederationRekrutierend» Google-Maps
Filial #1 Regional Oncology Dispensary of Nizhniy Novgorod
603081 Nizhny Novgorod
Russian FederationRekrutierend» Google-Maps
St. Petersburg SHI "City Clinical Oncology Dispensary"
197022 Saint-Petersburg
Russian FederationAktiv, nicht rekrutierend» Google-Maps
Multidisciplinary clinic Reaviz
443011 Samara
Russian FederationRekrutierend» Google-Maps
Volgograd Regional Clinical Oncology Dispensary
400138 Volgograd
Russian FederationAktiv, nicht rekrutierend» Google-Maps
Regional Clinical Oncology Hospital
150040 Yaroslavl
Russian FederationRekrutierend» Google-Maps
National University Hospital; National University Cancer Institute, Singapore (NCIS)
119228 Singapore
SingaporeRekrutierend» Google-Maps
National Cancer Centre; Medical Oncology
169610 Singapore
SingaporeAktiv, nicht rekrutierend» Google-Maps
Iatros International
9301 Bloemfontein
South AfricaRekrutierend» Google-Maps
Cancercare Langenhoven Drive Oncology Centre
6045 Port Elizabeth
South AfricaRekrutierend» Google-Maps
University of Pretoria Oncology Department; Medical Oncology
0002 Pretoria
South AfricaRekrutierend» Google-Maps
Eastleigh Breast Care Centre
0081 Pretoria
South AfricaRekrutierend» Google-Maps
Changhua Christian Hospital; Dept of Surgery
500 Changhua
TaiwanRekrutierend» Google-Maps
National Cheng Kung Uni Hospital; Dept of Hematology and Oncology
704 Tainan
TaiwanRekrutierend» Google-Maps
Chi-Mei Medical Centre; Hematology & Oncology
710 Tainan
TaiwanRekrutierend» Google-Maps
VETERANS GENERAL HOSPITAL; Department of General Surgery
00112 Taipei
TaiwanRekrutierend» Google-Maps
Chang Gung Memorial Hosipital at Linkou
333 Taoyuan City
TaiwanRekrutierend» Google-Maps
Chulalongkorn Hospital; Medical Oncology
10330 Bangkok
ThailandRekrutierend» Google-Maps
Rajavithi Hospital; Division of Medical Oncology
10400 Bangkok
ThailandAktiv, nicht rekrutierend» Google-Maps
Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc
10400 Bangkok
ThailandAktiv, nicht rekrutierend» Google-Maps
Maharaj Nakorn Chiang Mai Hosp; Surgery/Oncology
50200 Chang Mai
ThailandRekrutierend» Google-Maps
Songklanagarind Hospital; Department of Oncology
90110 Songkhla
ThailandRekrutierend» Google-Maps
Ankara City Hospital; Oncology
06800 Ankara
TurkeyAktiv, nicht rekrutierend» Google-Maps
Dicle University Faculty of Medicine
21280 Diyarbakir
TurkeyRekrutierend» Google-Maps
Kartal Dr Lutfi Kirdar Sehir Hastanesi; Medical Oncology Department
34000 Istanbul
TurkeyRekrutierend» Google-Maps
Prof. Dr. Cemil Tascioglu City Hospital; Med Onc
34384 Istanbul
TurkeyRekrutierend» Google-Maps
Katip Celebi University Ataturk Training and Research Hospital; Oncology
35360 Izmir
TurkeyRekrutierend» Google-Maps
Kocaeli University Faculty of Medicine; Medical oncology
31380 Izmit
TurkeyRekrutierend» Google-Maps
Zhytomyr Regional Oncology Center
10007 Zhytomyr
UkraineRekrutierend» Google-Maps
Kyiv City Clinical Oncological Center
03115 Kyiv
UkraineRekrutierend» Google-Maps
MI Kyiv Regional Council Kyiv Regional Oncological Dispensary; Department of Mammology
04107 Kyiv
UkraineRekrutierend» Google-Maps
RCI Sumy Regional Clinical Oncological Dispensary
40005 Sumy
UkraineRekrutierend» Google-Maps
Western General Hospital; Edinburgh Breast Unit
EH4 2XU Edinburgh
United KingdomRekrutierend» Google-Maps
Princess Alexandra Hospital; Oncology Department
CM20 1QX Harlow
United KingdomRekrutierend» Google-Maps
Barts Health NHS Trust; Cancer Research Delivery Group
EC1A 7BE London
United KingdomRekrutierend» Google-Maps
Guys & St Thomas Hospital; Department of Oncology
SE1 9RT London
United KingdomRekrutierend» Google-Maps
Nottingham City Hospital; Oncology
NG5 1PB Nottingham
United KingdomRekrutierend» Google-Maps
Peterborough City Hospital; Oncology Research Department 018
PE3 9GZ Peterborough
United KingdomRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Brief Summary:

This Phase II, randomized, open-label, multicenter study will evaluate the efficacy and

safety of giredestrant compared with physician's choice of endocrine monotherapy in

participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2

(HER2)-negative locally advanced or metastatic breast cancer who have received one or two

prior lines of systemic therapy in the locally advanced (recurrent or progressed) or

metastatic setting.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- For women who are premenopausal or perimenopausal and for men: treatment with approved

LHRH agonist therapy for the duration of study treatment

- Locally advanced (recurrent or progressed) or metastatic adenocarcinoma of the breast,

not amenable to treatment with curative intent

- Documented ER-positive tumor and HER2-negative tumor, assessed locally

- Disease progression after treatment with one or two lines of systemic therapy (but not

more than one prior targeted therapy) in the locally advanced (recurrent or

progressed) or metastatic setting

- Measurable disease as defined per RECIST v.1.1

- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

- Adequate organ function

Exclusion Criteria:

- Prior treatment with a selective estrogen receptor degrader (SERD), with the exception

of fulvestrant

- Treatment with any investigational therapy within 28 days prior to randomization

- Advanced, symptomatic, visceral spread that is at risk of life-threatening

complications

- Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or

leptomeningeal disease

- Active cardiac disease or history of cardiac dysfunction

- Pregnant or breastfeeding

Studien-Rationale

Primary outcome:

1. Progression-Free Survival, as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) (Time Frame - From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 40 months))



Secondary outcome:

1. Overall Survival (Time Frame - From randomization to death from any cause (up to 40 months))

2. Objective Response Rate, as Determined by the Investigator According to RECIST v1.1 (Time Frame - From randomization until disease progression or death (up to 40 months)):
The objective response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) on two consecutive occasions at least 4 weeks apart.

3. Duration of Response, as Determined by the Investigator According to RECIST v1.1 (Time Frame - From first occurrence of documented objective response to disease progression or death from any cause, whichever occurs first (up to 40 months))

4. Clinical Benefit Rate, as Determined by the Investigator According to RECIST v1.1 (Time Frame - From randomization until disease progression or death (up to 40 months)):
The clinical benefit rate is defined as the percentage of participants with stable disease for ≥24 weeks or a complete response (CR) or partial response (PR).

5. Investigator-Assessed Progression-Free Survival, in Subgroups Categorized by ESR1 Mutation Status (Time Frame - From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to 40 months))

6. Time to Deterioration in Pain Severity, Defined as the Time to First Documented ≥2-Point Increase from Baseline in the "Worst Pain" Item from the Brief Pain Inventory-Short Form (BPI-SF) Questionnaire (Time Frame - From Baseline until treatment discontinuation (up to 40 months))

7. Time to Deterioration in Pain Presence and Interference, Defined as the Time to First Documented ≥10-Point Increase from Baseline in the EORTC QLQ-C30 Linearly Transformed Pain Scale Score (Time Frame - From Baseline until treatment discontinuation (up to 40 months)):
EORTC QLQ-C30 = European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30

8. Time to Deterioration in Physical Functioning (PF), Defined as the Time to First Documented ≥10-Point Decrease from Baseline in the EORTC QLQ-C30 Linearly Transformed PF Scale Score (Time Frame - From Baseline until treatment discontinuation (up to 40 months))

9. Time to Deterioration in Role Functioning (RF), Defined as the Time to First Documented ≥10-Point Decrease from Baseline in the EORTC QLQ-C30 Linearly Transformed RF Scale Score (Time Frame - From Baseline until treatment discontinuation (up to 40 months))

10. Time to Deterioration in Global Health Status and Quality of Life (GHS/QoL), Defined as the Time to First Documented ≥10-Point Decrease from Baseline in the EORTC QLQ-C30 Linearly Transformed GHS/QoL Scale Score (Time Frame - From Baseline until treatment discontinuation (up to 40 months))

11. Number of Participants with Adverse Events, Severity Determined According to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) (Time Frame - From Baseline until 30 days after final dose of study drug (up to 40 months))

12. Number of Participants with Vital Sign Abnormalities Over the Course of the Study (Time Frame - Assessed at Baseline and predose on Day 1 of every cycle (1 cycle is 28 days) until 30 days after the final dose of study drug (up to 40 months)):
Vital signs include respiratory rate, pulse rate, systolic and diastolic blood pressure while the patient is in a seated position, and temperature.

13. Number of Participants with Clinical Laboratory Test Abnormalities for Hematology Parameters Over the Course of the Study (Time Frame - Assessed at Baseline and predose on Day 1 of every cycle (1 cycle is 28 days) until 30 days after the final dose of study drug (up to 40 months))

14. Number of Participants with Clinical Laboratory Test Abnormalities for Biochemistry Parameters Over the Course of the Study (Time Frame - Assessed at Baseline and predose on Day 1 of every cycle (1 cycle is 28 days) until 30 days after the final dose of study drug (up to 40 months))

15. Plasma Concentration of Giredestrant at Specified Timepoints (Time Frame - Predose and postdose on Day 1 of Cycles 1 and 2, predose on Day 1 of Cycles 3, 5, 7, 9, 11, 13, and 15 (1 cycle is 28 days), and 30 days after final dose of study drug (up to 40 months))

Studien-Arme

  • Experimental: Giredestrant
  • Active Comparator: Physician's Choice of Endocrine Monotherapy
    The physician's choice of endocrine monotherapy will be limited to fulvestrant or an aromatase inhibitor.

Geprüfte Regime

  • Giredestrant (GDC-9545 / RO7197597 / RG6171 / ):
    Giredestrant is taken orally once per day on Days 1-28 of each 28-day cycle.
  • Fulvestrant or an Aromatase Inhibitor (Physician's Choice):
    Physician's choice of endocrine monotherapy (fulvestrant or an aromatase inhibitor) is taken in accordance with the local prescribing information for the respective product.
  • LHRH Agonist:
    Only premenopausal/perimenopausal participants and male participants will receive a luteinizing hormone-releasing hormone (LHRH) agonist on Day 1 of each 28-day treatment cycle. The investigator will determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
EHA 2021
  • SCD: Häufigere und längere VOC-bedingte Krankenhausaufenthalte nach Vorgeschichte von VOC-Hospitalisierungen – Ergebnisse einer Beobachtungsstudie
  • Real-World-Daten des ERNEST-Registers untermauern Überlebensvorteil unter Ruxolitinib bei primärer und sekundärer Myelofibrose
  • I-WISh-Studie: Ärzte sehen TPO-RAs als beste Option, um anhaltende Remissionen bei ITP-Patienten zu erzielen
  • Phase-III-Studie REACH2 bei steroidrefraktärer akuter GvHD: Hohes Ansprechen auf Ruxolitinib auch nach Crossover
  • SCD: Neues digitales Schmerztagebuch zur tagesaktuellen Erfassung von VOCs wird in Beobachtungsstudie geprüft
  • Französische Real-World-Studie: Eltrombopag meist frühzeitig nach ITP-Diagnose im Rahmen eines Off-label-Use eingesetzt
  • Fortgeschrittene systemische Mastozytose: Französische Real-World-Studie bestätigt klinische Studiendaten zur Wirksamkeit von Midostaurin
  • CML-Management weitgehend leitliniengerecht, aber verbesserungsfähig – Ergebnisse einer Querschnittsbefragung bei britischen Hämatologen
  • Britische Real-World-Studie: Kardiovaskuläres Risikomanagement bei MPN-Patienten in der Primärversorgung nicht optimal
  • Myelofibrose: Früher Einsatz von Ruxolitinib unabhängig vom Ausmaß der Knochenmarkfibrose